期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

氟康唑联合特比萘芬抗白念珠菌的体外药敏实验 被引量：1

下载PDF
导出
摘要 采用NCCLS公布的M27-A方案微量稀释法测定氟康唑、特比荼芬对35株临床分离的白念珠菌的药敏结果,应用棋盘微量稀释法测定氟康唑、特比萘芬二者联合对35株白念珠菌的药敏结果氟康唑和特比萘芬联用MIC几何平均数较其单独应用均显著降低(t=8.405,P<0.01;t=12.976,P<0.01),22株有协同作用,12株有相加作用,1株为无关作用,未发现拮抗作用。二者联用敏感株增加,耐药株减少。氟康唑与特比萘芬联合应用能够增强抗白念珠菌的作用。
作者 于晓虹 杨国玲 刘晓明 王华
机构地区 大连医科大学附属第一医院皮肤科
出处 《中国麻风皮肤病杂志》 2009年第11期826-828,共3页 China Journal of Leprosy and Skin Diseases
关键词 白念珠菌 氟康唑 特比萘芬
分类号 R96 [医药卫生—药理学]
  • 相关文献

参考文献7

  • 1Ghannoum MA, Elewski B. Successful treatment of fluconazole - resistant oropharyngeal candidiasis by a combination of fluconazole and terbinafine. Clin Diagn Lab Immunol 1999 ; 6 (6) : 921 - 923.
  • 2Michael Weig, Frank - Michael C. Synergism of voriconazole and terbinafine against eandida albieans isolates from human immunodeficiency virus-infected patients with oropharyngeal candidiasis. Antimicrob Agents Chemother 2001 ;45(3) :966 - 968.
  • 3National Conunittee for Clinical Laboratory standards. Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved Standard M27 - A. National Committee for Clinical Laboratory standards Wayne Pa. NCCLS 1997 ; 17(9) : 1.
  • 4王文莉,王端礼,李若瑜,王晓红,万哲.酵母菌的 NCCLS 药敏试验方法及其应用[J].中华医学检验杂志,1997,20(2):119-122. 被引量：37
  • 5江惟苏,陈荣,谭升顺,陈庆秀.特比萘芬与氟康唑或伊曲康唑体外联合抗白念珠菌的作用[J].中国抗生素杂志,2005,30(9):568-571. 被引量：7
  • 6沈亮亮,叶元康.氟康唑与5-氟胞嘧啶体外联合抗白念珠菌临床分离株的研究[J].同济大学学报（医学版）,2005,26(6):19-21. 被引量：10
  • 7Mosquera J, Sharp A, Moore CB, et al. In vitro interaction of terbinafine with itraconazole, fluconazole, amphotericin B and 5-flucytosine against Aspergillus spp. J Antimicrob Chemother 2002; 50(2) : 189.

二级参考文献21

  • 1He XG，Antimicrob Agents Chemother，1994年，38卷，2495页
  • 2Citak S,Ozcelik B,Cesur S,Abbasoglu U.In vitro susceptibility of Candida species isolated from blood culture to some antifungal agents [ J ].Jpn J Infect Dis,2005 ,58(1) :44- 6.
  • 3Makimura K,Oguri T,Mikami Y,et al.Multicenter evaluation of commercial frozen plates for microdilution broth antifungal susceptibility testing of yeasts and comparison of MIC limits recommended in NCCLS M27- A2 [ J ].Microbiol Immunol,2005,49(2) :97-106.
  • 4van de Sande WW,Luijendijk A,Ahmed AO,et al.Testing of the in vitro susceptibilities of Madurella mycetomatis to six antifungal agents by using the Sensititre system in comparison with a viability - based 2,3 - bis ( 2 -methoxy- 4 - nitro- 5 - sulfophenyl) - 5 - [ (phenylamino) carbonyl ] - 2H - tetrazolium hydroxide (XTT)assay and a modified NCCLS method[J].Antimicrob Agents Chemother,2005 ,49(4):1364 - 1368.
  • 5Uchida K,Nishiyama Y.In vitro antifungal activity of luliconazoleJ(NND- 502),a novel imidoazole antifungal agents[J].Infect Chemother,2004,10(4) :216 - 219.
  • 6Berthet N ,Faure O ,Bakri A,et al.In vitro susceptibility of Aspergillus spp,clinical isolates to albendazole[J].J Antimicrob Chemother,2003 ,51 (6):1419 - 1422.
  • 7National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of yeasts, Approved Standard M27-A [S]. Wayne, PA: NCCLS,1997,17(9):1.
  • 8Mosquera J, Sharp A, Moore C B, et al. In vitro interaction of terbinafine with itraconazole, fluconazole, amphotericin B and 5-flucytosine against Aspergillus spp.[J]. J Antimicrob Chemother, 2002,50(2) : 189.
  • 9Perea S, Gonzalez G, Annette W, et al. In vitro activities of terbinafine in combination with fluconazole, itraconazole, voriconazole, and posaconazole against clinical isolates of Candida glabrata with decreased susceptibility to azole[J]. J Clin Microbiol,2002,40(5) : 1831.
  • 10Czaika V, Tietz H J, Schmalreck A, et al. Antifungal susceptibility testing in chronically recurrent vaginal candidiasis as basis for effective therapy [J]. Mycoses,2000,43(Suppl 2) :45.

共引文献50

同被引文献4

引证文献1

二级引证文献1

中国麻风皮肤病杂志
2009年 第11期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部